Citigroup reiterated their buy rating on shares of Smith & Nephew (LON:SN – Get Rating) in a report published on Tuesday morning, Marketbeat.com reports.
A number of other brokerages have also issued reports on SN. Liberum Capital upgraded shares of Smith & Nephew to a buy rating and upped their target price for the stock from GBX 1,120 ($13.65) to GBX 1,410 ($17.18) in a research report on Wednesday, March 1st. Barclays lowered their target price on shares of Smith & Nephew from GBX 1,500 ($18.28) to GBX 1,480 ($18.04) and set an overweight rating for the company in a research note on Wednesday, February 22nd. Finally, Berenberg Bank reaffirmed a buy rating and issued a GBX 1,400 ($17.06) target price on shares of Smith & Nephew in a research note on Wednesday, March 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Smith & Nephew currently has an average rating of Moderate Buy and an average price target of GBX 1,405.50 ($17.13).
Smith & Nephew Price Performance
Shares of SN stock opened at GBX 1,197.50 ($14.59) on Tuesday. Smith & Nephew has a 1 year low of GBX 959.20 ($11.69) and a 1 year high of GBX 1,338.50 ($16.31). The firm’s 50 day moving average is GBX 1,165.69 and its 200-day moving average is GBX 1,093.50. The firm has a market capitalization of £10.46 billion, a price-to-earnings ratio of 5,630.95, a PEG ratio of 1.31 and a beta of 0.35. The company has a current ratio of 2.25, a quick ratio of 0.84 and a debt-to-equity ratio of 54.61.
Smith & Nephew Increases Dividend
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.